Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

328
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
328
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

1.4K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.4K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

71
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
71
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

613
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
613
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

1.2K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.2K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

869
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
869

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antenatal Corticosteroid Exposure in Late Preterm Infants: Clinical Considerations in Diabetic Mothers.

Cureus·2026
Same author

Polyunsaturated Fatty Acid Balance Modulates Microglial State in a Murine Model of Oxygen-Induced Neovascularization.

Nutrients·2026
Same author

Canadian Stroke Best Practice Recommendations: Rehabilitation, Recovery and Community Participation Following Stroke. Part One: Stroke Rehabilitation Planning for Optimal Care Delivery, 7th Edition Update 2025.

American journal of physical medicine & rehabilitation·2025
Same author

Canadian Stroke Best Practice Recommendations Rehabilitation, Recovery, and Community Participation Following Stroke, Part Two: Delivery of Stroke Rehabilitation to Optimize Functional Recovery, 7th Edition Update 2025.

American journal of physical medicine & rehabilitation·2025
Same author

Canadian Stroke Best Practice Recommendations Rehabilitation, Recovery, and Community Participation Following Stroke, Part Three: Optimizing Activity and Community Participation Following Stroke , 7th Edition Update, 2025.

American journal of physical medicine & rehabilitation·2025
Same author

Polyunsaturated fatty acid balance modulates microglial state in a murine model of oxygen-induced neovascularization.

Research square·2025

Related Experiment Video

Updated: Mar 28, 2026

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

22.5K

Lusutrombopag: First Global Approval.

Esther S Kim1

  • 1Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand. dru@adis.com.

Drugs
|December 16, 2015
PubMed
Summary
This summary is machine-generated.

Lusutrombopag is an oral medication that safely increases platelet counts in patients with chronic liver disease (CLD) and thrombocytopenia. This drug supports patients undergoing invasive surgery by improving their low platelet levels.

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

6.1K
Automated Counterflow Centrifugal System for Small-Scale Cell Processing
04:49

Automated Counterflow Centrifugal System for Small-Scale Cell Processing

Published on: December 12, 2019

9.9K

Related Experiment Videos

Last Updated: Mar 28, 2026

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

22.5K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

6.1K
Automated Counterflow Centrifugal System for Small-Scale Cell Processing
04:49

Automated Counterflow Centrifugal System for Small-Scale Cell Processing

Published on: December 12, 2019

9.9K

Area of Science:

  • Pharmacology
  • Hepatology
  • Hematology

Background:

  • Thrombocytopenia is a common complication in patients with chronic liver disease (CLD).
  • Low platelet counts pose significant risks for patients undergoing invasive surgical procedures.
  • Current treatment options for CLD-associated thrombocytopenia are limited, especially for surgical candidates.

Purpose of the Study:

  • To summarize the development milestones of lusutrombopag, a novel thrombopoietin (TPO) receptor agonist.
  • To highlight the drug's journey leading to its first global approval for CLD patients with thrombocytopenia.
  • To provide an overview of lusutrombopag's mechanism of action and clinical significance.

Main Methods:

  • Lusutrombopag selectively targets the human thrombopoietin (TPO) receptor.
  • Activation of TPO receptor pathways promotes megakaryocyte proliferation and differentiation.
  • Clinical development involved assessing safety and efficacy in patients with CLD and thrombocytopenia.

Main Results:

  • Lusutrombopag demonstrated effective platelet count increase in patients with CLD-associated thrombocytopenia.
  • The drug's oral bioavailability and selective TPO receptor agonism were key development features.
  • Achieved first global regulatory approval in Japan in September 2015.

Conclusions:

  • Lusutrombopag represents a significant advancement in managing thrombocytopenia in CLD patients.
  • The drug offers a new therapeutic option for improving platelet levels prior to elective invasive surgery.
  • Successful development and approval underscore the potential of targeted TPO receptor agonism.